Knowledge Management Advisory Board

Our Goals

Highlight the importance of knowledge management in strategic decision making.
Improve the culture of decision making at healthcare companies.
Make sure people who are improving knowledge management are elevated, not made redundant.

Background

At inPhronesis, we care a lot about knowledge management and we want to help the industry as a whole to improve its decision making. We also believe we shouldn't be developing a product in a vacuum. This led us to build the Knowledge Management Advisory Board (KMAB) and to make sure that we include both existing customers as well as outside experts and even people outside our industry, who can help to research and drive improvements in how knowledge management can help drive strategic decision making.

Our Work

The Knowledge Management Advisory Board just published their first collaborative paper, "Selecting A Compound For Drug Development –
The Importance Of Knowledge Management" and has discussed the findings and implications of this work in a recent webinar series. They are currently working on a follow up survey and a second set of webinars to further refine the concept and drive data driven discussion.

Diana Gowe Kolek

Global Strategic Analytics, J&J

Diana provides leadership and strategic direction to the Global Commercial Insights & Analytics team. She’s responsible for driving functional excellence and efficiency in competitive intelligence, championing talent, and implementing compliant processes across GCSO (Global Commercial Strategy Organization). As a strategic partner, Diana partners across the GCSO Therapeutic Area (TA) analytics group and leaders to determine appropriate functional methodologies and capabilities to support emerging and existing business drivers and trends. She also oversees management of internal and external data sources, tools & budgets.

Diana joined Janssen in 2001 and spent 7 years at Ortho McNeil Pharmaceuticals, where she provided business intelligence in support of the CNS franchise. In 2009 she transitioned to the Global Commercial Strategy Organization where she built the Global Business Intelligence Function. She is now part of the Portfolio, Innovation & Commercialization Strategy team. Prior to joining Johnson & Johnson, she spent 17 years at Knoll Pharmaceuticals in roles of increasing responsibility, delivering scientific and business intelligence. Diana holds a Masters Degree in Library and Information Science from Rutgers University, and a Bachelor’s Degree in Health Sciences from William Paterson University.

John Panaccione

Co-Founder, Folla Capital

John Panaccione is the co-founder of Folla Capital; an SEC-registered broker-dealer focused on helping small businesses and startups raise capital. He holds Series 7 (General Securities Representative), 24 (General Securities Principal), 79 (Investment Banking), and 63 (Uniform Securities Agent State Law) SEC licenses. Before launching Folla Capital in 2020, he co-founded and led a software company called the LogicBay Corporation from its launch in 2003 to its sale to Pluribus Technologies in 2020. During that time, he learned everything there is to know about the challenging world of small business finance the only way you can – the hard way - by doing.

Along the way, in 2013, John also co-founded a non-profit VETtoCEO with another Army veteran-turned-business-owner. VETtoCEO’s mission is to help transitioning military members explore small business ownership as a viable career path when leaving military service. In 2022, he merged VETtoCEO with Warrior Rising. Before catching the entrepreneurial bug, he worked in operations and sales leadership roles in several small and large corporations. John proudly served as a U.S. Army officer for six years, mostly in various leadership roles in paratrooper units in the 82nd Airborne Division. He earned a B.S. in Criminal Justice and an M.B.A. with a Management of Technology and Operations focus, both from Bryant University.

Anna Skabeev

Anna Skabeev, MD, MBA is a strategic leader with over 15 years in a biopharma industry, with experience supporting products across life cycle, as well as working across alliances. Most recently, she was a Senior Director, Alliance Management at Karyopharm Therapeutics. Prior to joining Karyopharm Anna was at Sanofi Genzyme leading a global competitive intelligence team for DUPIXENT across indications. Anna also held competitive intelligence (CI) roles at Biogen and Ironwood.

Through her experience in CI, Anna became passionate about knowledge management solutions that enable timely and actionable decision-making and provided input into inVision in its early development stage.

Anna’s other roles in the biopharma industry included patient engagement, clinical trial recruitment, decision support and marketing. Anna has an MD from St. Petersburg Pediatric Medical Academy in Russia and an MBA from Suffolk University, Boston, MA.

Hari Patel

Sr. Director Portfolio & Product Development, BioMarin Pharmaceutical Inc.

Hari is a Core Team Leader at BioMarin, a mid-size rare disease company. As a cross-functional leader, he works across modalities and life-cycle management for pipeline and launched therapeutics. Hari has held progressive leadership roles over his 20+ years within the industry. Hari spent nine years at Genentech building the Market Analytics and Strategy group. He led immunology, ophthalmology, and non-onc commercial strategy and planning teams to defend against competitor and biosimilar launches. Before Genentech, Hari held roles in Sales, Global Marketing, Corporate Strategy, and Business Development.

Hari holds an MBA, an MHA, and a Bachelor of Science in Biology from the University of Pittsburgh. He resides in the east bay with his wife, Reena, and two kids.

Knowledge Management Advisory Board

Driving best practices around knowledge management for the Pharma industry